These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31358408)

  • 1. A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children.
    Janewongwirot P; Jantarabenjakul W; Anugulruengkitt S; Anunsittichai O; Saengseesom W; Buranapraditkun S; Sophonphan J; Wacharachaisurapol N; Jitrungruengnij N; Pancharoen C; Puthanakit T
    Vaccine; 2019 Aug; 37(36):5307-5313. PubMed ID: 31358408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Houillon G
    Vaccine; 2019 Apr; 37(16):2268-2277. PubMed ID: 30890382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
    Kerdpanich P; Chanthavanich P; De Los Reyes MR; Lim J; Yu D; Ama MC; Mojares Z; Casula D; Arora AK; Pellegrini M
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006340. PubMed ID: 29874228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial.
    Pichon S; Guinet-Morlot F; Minutello M; Donazzolo Y; Rouzier R; Chassard D; Fitoussi S; Hou V
    Vaccine; 2013 Apr; 31(18):2295-301. PubMed ID: 23510665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Rasuli A; Houillon G
    Vaccine; 2020 May; 38(21):3740-3746. PubMed ID: 32280042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of 2-dose pre-exposure rabies vaccine co-administered with quadrivalent influenza vaccine in children.
    Chantasrisawad N; Jantarabenjakul W; Anugulruengkitt S; Punrin S; Limsuwun K; Sawangsinth P; Phasomsap C; Sophonphan J; Pancharoen C; Puthanakit T
    Int J Infect Dis; 2021 Nov; 112():89-95. PubMed ID: 34547486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
    Pineda-Peña AC; Jiang Q; Petit C; Korejwo-Peyramond J; Donazzolo Y; Latreille M; Homery MC; Babin V; Benamor S; Pichon S; Guinet-Morlot F; Minutello AM
    Clin Infect Dis; 2024 Jun; 78(6):1748-1756. PubMed ID: 38478634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV).
    Shanbag P; Shah N; Kulkarni M; Juvekar M; Madhusudana SN; Vakil HB; Malerczyk C
    Hum Vaccin; 2008; 4(5):365-9. PubMed ID: 18398307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Response Following Pre-Exposure Immunization Against Rabies in High-Risk Professionals.
    Dougas G; Mavrouli M; Vrioni G; Lytras T; Mellou K; Metallidis S; Istikoglou I; Mitrou K; Tzani M; Georgopoulou I; Tsalikoglou F; Garetsou E; Poulakou G; Giannitsioti E; Moschopoulos C; Baka A; Georgakopoulou T; Tsiodras S; Tsakris A
    Vector Borne Zoonotic Dis; 2020 Apr; 20(4):303-309. PubMed ID: 31794689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe.
    Kamoltham T; Thinyounyong W; Phongchamnaphai P; Phraisuwan P; Khawplod P; Banzhoff A; Malerczyk C
    J Pediatr; 2007 Aug; 151(2):173-7. PubMed ID: 17643772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.
    Zhang X; Zhu Z; Wang C
    Clin Vaccine Immunol; 2011 Sep; 18(9):1477-9. PubMed ID: 21752947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country.
    Angsuwatcharakon P; Ratananpinit N; Yoksan S; Saengseesom W; Sriaksorn R; Raksahket N; Tantawichien T
    Vaccine; 2020 Jul; 38(32):5015-5020. PubMed ID: 32522414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen.
    Kalimuddin S; Wijaya L; Chan YFZ; Wong AWL; Oh HML; Wang LF; Kassim JA; Zhao J; Shi Z; Low JG
    Vaccine; 2017 Dec; 35(51):7127-7132. PubMed ID: 29174316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
    Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S
    Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety.
    Quiambao BP; Lim JG; Bosch Castells V; Augard C; Petit C; Bravo C; Delore V; Houillon G
    Vaccine; 2022 Aug; 40(36):5347-5355. PubMed ID: 35933278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.
    Li R; Li Y; Wen S; Wen H; Nong Y; Mo Z; Xie F; Pellegrini M
    Hum Vaccin Immunother; 2015; 11(2):435-42. PubMed ID: 25692350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Pichon S; Moureau A; Petit C; Chu L; Essink B; Muse D; Saleh J; Guinet-Morlot F; Minutello AM
    Vaccine; 2022 Aug; 40(33):4780-4787. PubMed ID: 35778281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.